Enterprise Value

300M

Cash

52.86M

Avg Qtr Burn

-50.97M

Short % of Float

18.35%

Insider Ownership

1.21%

Institutional Own.

50.30%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

BLA

Submission

Botensilimab (AGEN1181) (anti-CLTA-4) Details
Cancer, Melanoma, Pancreatic cancer

Phase 2

Data readout

AGEN1777 (BMS-986442) (TIGIT)+ nivolumab and/or chemotherapies Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s, Lung cancer

Phase 2

Update

Phase 1b

Data readout

Botensilimab (AGEN1181) Details
Cancer, Non-small cell lung carcinoma

Phase 1b

Data readout

Phase 1b

Update

AGEN2373 w/ Botensilimab (AGEN1181) Details
Solid tumor/s, Cancer, Melanoma

Phase 1b

Update

Phase 1

Data readout

Balstilimab (AGEN2034) Details
Cancer, Cervical cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued